NASH and Fibrosis


Cambridge Healthtech Institute 第1届
非酒精性脂肪性肝炎与纤维化
脂肪肝疾病、特发性肺纤维化等各种纤维症领域的新药发现

第15届Discovery on Target其中一环

本会议以非酒精性脂肪性肝炎 (NASH) 与纤维化为主题,将分享快速进步的新治疗药物候补最新趋势,讨论这个越来越重要的医疗领域的新药发现策略。

Final Agenda


RECOMMENDED ALL ACCESS PACKAGE:

· September 25 Symposium: Targeting HBV

· September 25 Short Course: Immunology Basics for Chemists

· September 26-27 Conference: NASH and Fibrosis

· September 27-28 Conference: Autoimmune and Inflammation Drug Targets

· September 27 Short Course: Practical Phenotypic Screening

· September 28-29 Symposium: Tackling Rare Diseases


Tuesday, September 26

7:00 am Registration Open and Morning Coffee

NASH Drug Candidates

8:00 Welcome Remarks

Anjani Shah, Ph.D., Conference Director, Cambridge Healthtech Institute

8:05 Chairperson's Opening Remarks

H. James Harwood Jr., Ph.D., Founder and CEO, Delphi BioMedical Consultants, LLC

8:10 KEYNOTE PRESENTATION: NASH Basic Science Overview and Medical Landscape

Kathleen Elizabeth Corey, M.D., Assistant Professor of Medicine, Massachusetts General Hospital

8:40 Updates on a Dual PPAR Agonist in Clinical Development for Treating NASH

Bart Staels, Ph.D., Co-Founder, GENFIT

9:10 Progress in the Development of FXR Agonists

Yat Sun Or, Ph.D., Senior Vice President, R&D and CSO, Enanta Pharmaceuticals, Inc.

FXR agonism is under investigation as a potential treatment for multiple metabolic and liver conditions, including NASH. A brief overview of FXR agonists in early clinical trials will be presented, as well as the preclinical data illustrating EDP-305 selectivity for FXR, its significant perturbation of FXR-dependent gene expression, and its striking effects on hepatocyte ballooning and liver fibrosis in multiple animal models.

9:40 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

NASH Drug Candidates (Cont.)

10:25 FXR Agonists in Phase II Development for NASH

Bryan Lafitte, Ph.D., Director, Discovery Pharmacology, Genomics Institute of the Novartis Research

10:55 Cenicriviroc, a Dual CCR2 and CCR5 Antagonist, for the Treatment of Liver Fibrosis in Adults with Nonalcoholic Steatohepatitis

Eric Lefebvre, M.D., Vice President, Head of Clinical Research and Development - NASH, Allergan

The CENTAUR Phase IIb study evaluated the oral chemokine receptor CCR2/5 antagonist cenicriviroc (CVC) in non-alcoholic steatohepatitis and liver fibrosis in adults at increased risk of progression to cirrhosis. CVC was well tolerated, with twice as many patients achieving ≥1-stage improvement in fibrosis and no steatohepatitis worsening vs. placebo after 1 year. Patients with higher disease activity and fibrosis stage showed greater numerical improvements in fibrosis.

11:25 Thyroid Hormone Receptor Targets

Rebecca Taub, M.D., CMO & Executive Vice President, R&D, Madrigal Pharmaceuticals

11:55 Sponsored Presentation (Opportunity Available)

12:25 pm Session Break

12:35 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:15 Refreshment Break in the Exhibit Hall with Poster Viewing

Liver Fibrosis: Emerging Targets and Tools

1:50 Chairperson's Remarks

Bryan C. Fuchs, Ph.D., Assistant Professor of Surgery, Harvard Medical School

1:55 FEATURED PRESENTATION: Tools for Assessing Fibrosis and Monitoring Response to Treatment in Preclinical Models

Bryan C. Fuchs, Ph.D., Assistant Professor of Surgery, Harvard Medical School

There are a number of anti-fibrotic therapies entering clinical trials in NASH patients, but a major obstacle to their development is the lack of sensitive and noninvasive tools for assessing fibrosis. Here, we discuss our preclinical work to develop molecular imaging as a biomarker that could not only be used to select patients for clinical trials but also provide an early assessment of treatment efficacy.

2:25 Targeting Liver Fibrosis through Modulating the Wnt Pathway

Weilin Xie, Ph.D., Senior Principal Scientist, Biotherapeutics, Celgene

2:55 Sponsored Presentation (Opportunity Available)

3:25 Refreshment Break in the Exhibit Hall with Poster Viewing and Poster Competition Winner Announced

Liver Fibrosis: Emerging Targets and Tools (Cont.)

4:05 FAP and FGF21: Complementary Targets for the Treatment of NASH

Travis W. Bainbridge, MS, Senior Scientific Researcher, Department of Protein Chemistry, Genentech, Inc.

Fibroblast activation protein (FAP) is a membrane-bound protease expressed at sites of tissue remodeling, inflammation and fibrosis. FGF21 is a hepatoprotective hormone we identified as an FAP substrate. Cleavage by FAP inactivates FGF21, while FAP inhibition increases endogenous levels of active FGF21, making FAP an attractive target for liver disease. Additionally, a FAP-specific activity assay for monitoring the pharmacodynamics of FAP inhibitors will be described.

4:35 Targeting Ammonia with OCR-002 Reduces the Progression of Non-Alcoholic Fatty Liver Disease

Rajiv Jalan, M.D., Ph.D., Professor of Hepatology, University College London

NAFLD is characterized by reduced activity of key urea cycle enzymes resulting in hyperammonemia. Pathophysiological concentrations of ammonia produce activation of stellate cells, which can be reversed by administration of the ammonia-lowering drug, OCR-002. Treatment of a rodent model of NAFLD (high-fat high-cholesterol diet) with OCR-002 prevented progression of fibrosis, providing proof of concept for an ammonia lowering therapy in NAFLD that can be readily translated.

5:05 Interactive Breakout Discussion Groups

Join a breakout discussion group. These are informal, moderated discussions with brainstorming and interactive problem solving, allowing participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic. Details on the topics and moderators are available on the conference website.

6:05 Welcome Reception in the Exhibit Hall (Sponsorship Opportunity Available)

7:10 Close of Day

Wednesday, September 27

7:30 am Registration Open and Morning Coffee

Non-Liver Fibrosis

8:00 Chairperson's Remarks

Rebecca Taub, M.D., CMO & Executive Vice President, R&D, Madrigal Pharmaceuticals

8:05 Roles of LPA and S1P in Lung and Dermal Fibrosis

Andrew Tager, M.D., Associate Professor of Medicine, Harvard Medical School

8:35 Epigenetic Targets for Cardiorenal Fibrosis

Timothy A. McKinsey, Ph.D., Director, Consortium for Fibrosis Research & Translation, Department of Medicine, University of Colorado - Anschutz Medical Campus

Despite the well-accepted roles for fibrosis in the pathogenesis of heart failure and chronic kidney disease, there are no FDA-approved therapies to combat excessive extracellular matrix deposition in cardiac or renal tissue. I will discuss our recent findings suggesting that specific epigenetic regulatory proteins serve crucial pro-fibrotic functions, and the potential for small molecule inhibitors of these factors for the treatment of cardiorenal fibrosis.

9:05 Sponsored Presentation (Opportunity Available)

9:35 Coffee Break in the Exhibit Hall with Poster Viewing

Non-Liver Fibrosis (Cont.)

10:20 Moving from Lung Fibrosis to Liver Fibrosis

Ying Luo, Ph.D., CEO, GNI Group

A new compound targeting liver fibrosis has shown excellent efficacy in liver fibrosis and kidney fibrosis animal models. It also showed significantly improved safety profile over pirfenidone in Phase I studies. Currently, it is in a 240 patient Phase II studies for HBV-associated liver fibrosis in China.

10:50 The Development of PAT-1251, a Small Molecule LOXL2 Inhibitor to Treat Fibrosis

John Hutchinson, Ph.D., President and CSO, PharmAkea

LOXL2 catalyzes oxidation of ε-amines of lysine residues within collagen, generating reactive aldehydes that condense to form collagen cross-linkages. Dysregulation of this process can lead to fibrosis. PAT-1251 was identified as a potent irreversible inhibitor of LOXL2 that is highly selective over LOX and other AOs. PAT-1251 significantly reduced fibrosis in mouse lung bleomycin models and has completed healthy volunteer Phase I trials.

11:20 Enjoy Lunch on Your Own

12:20 pm Plenary Keynote Program

(click here for details)

2:00 Refreshment Break in the Exhibit Hall with Poster Viewing

2:45 Close of Conference

* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English

Catalog

Celebrating 25 Years

Submit A Poster

View All Sponsors

View Media Partners



免费电子邮件通知服务